J&J ($JNJ) drops Arena ($ARNA) diabetes drug pact

Johnson & Johnson ($JNJ) has decided to end its deal for Arena Pharmaceuticals' ($ARNA) diabetes drug APD597 after seeing Phase I results. APD597 is a GPR119 agonist for type 2 diabetes, which, along with other compounds and intellectual property, will revert to Arena upon termination of the collaboration. Arena release

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.